Dr. Xian Chen has multi-disciplinary expertise in mass spectrometry (MS)-based proteomics and proteogenomics, immunology, signaling and epigenetic regulation of inflammation, cancer biology, molecular and cellular biology. His pioneering work on introducing mass tags with stable isotopes, termed amino acid-coded mass tagging (AACT), a.k.a. SILAC, as a widely used strategy in proteomic research, was recognized in 1999 with the prestigious Presidential Early Career Award for Scientists and Engineers. He is also the inventor of an array of functional proteomic approaches for the discovery of disease markers and new drug targets, including Chromatin-activity-based Chemoproteomics (ChaC) and multi-omics iC-MAP and SeCEP. Dr. Chen has a long-standing interest in understanding the molecular pathways and mechanisms underlying chronic inflammation-associated diseases such as cancer, Alzheimer’s disease, diabetes, and COVID-19. He has trained 50+ lab members including five professors in major US universities. In multiple research areas he has authored and co-authored more than 160 papers including some in high impact journals such as Nature, Science, Cell Stem Cell, Cell, Nature Immunology, Molecular Cell, Immunity, Cancer Discovery, Nature Cancer, Cell Reports, Science Advances, Nature Communications, Cell Chemical Biology, iScience, etc. He also holds five patents for his technology innovations and a provisional patent application for ‘New Therapeutics for Alzheimer’s disease’. His H-index is at 60 with 32,440 citations.